Biomarkers

Highlights from CTAD 2022

Clinical implementations of AlzoSure Predict

Predicting tau-PET signal in early Alzheimer’s disease using speech biomarkers

Blood-based biomarkers as surrogates of amyloid burden in preclinical Alzheimer’s disease

Promise of exosomal proteins as biomarkers in Alzheimer’s disease

Speech biomarker for cognition: a novel marker for AD clinical trial screening

Is amyloid load a valid surrogate endpoint for AD clinical trials?

Astrocyte biomarkers associated with amyloid-β and tau pathologies

Identifying dementia with Lewy bodies in the presence of Alzheimer’s disease

Performance of plasma p-tau181 as a community-based screening tool for AD clinical trials

Associations between predicted brain age and Alzheimer’s Disease biomarkers

Can biomarkers help to predict brain age?

The diagnostic and prognostic performance of U-p53AZ as a blood-based biomarker for AD

The value of plasma p-tau181 as a screening and diagnostic tool for Alzheimer’s disease

Understanding the effect of other diseases on blood biomarker levels in AD

Use of machine learning in Alzheimer’s disease